Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan dual or triple therapy versus lansoprazole triple therapy for Helicobacter pylori eradication
2019-002668-28Phase 3Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vonoprazan, lansoprazole, amoxicillin and clarithromycin in Helicobacter pylori infection (3 arms), sponsored by Phathom Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
vonoprazanlansoprazoleamoxicillinclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on 2019-002668-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002668-28.